ICF004 / Changfeng Pharmaceutical - LARVOL DELTA

ICF004-INH: The Safety and PK Study of Inhaled ICF004 in Healthy Chinese Volunteers (clinicaltrials.gov) - P1 | N=73 | Not yet recruiting | Sponsor: Ruijin Hospital

New P1 trial • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

CF PharmTech…is pleased to announce that the investigational new drug ('IND') application for ICF004, a Class 1 new drug (the 'Product'), was recently approved by the National Medical Products Administration of the People’s Republic of China (the 'NMPA') (HKEXnews) - "The Product is intended for the treatment of interstitial lung disease (ILD), a disease area that includes indications such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)."

New trial • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease

CF PharmTech, Inc…announced that the Investigational New Drug (“IND”) application for ICF004, the Company’s internally developed first-in-class (FIC) inhaled dry powder candidate for the treatment of pulmonary fibrosis (a Class 1 chemical drug candidate), has been accepted by the National Medical Products Administration of China (“NMPA”). (Financial Times)

New trial • Idiopathic Pulmonary Fibrosis